Five9 Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Five9 Inc trades at $33.37 (market cap $2.65B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 3.2× Five9 Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FIVN | HNGE | |
|---|---|---|
Market Cap | $2.65B | $8.48B |
Volume | 971,747 | 879,799 |
Sector | Technology | Health |
52-Week High | $38.65 | $105.14 |
52-Week Low | $13.61 | $31.17 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.80B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.08, down 7.26% today amid recent volatility, though the stock remains near its 52-week high of $39.55. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and accelerating AI revenue growth reaching 78% year-over-year. Technical indicators suggest a bullish trend with moving averages supporting upside potential, while RSI levels remain neutral. Five9 maintains leadership in the contact center-as-a-service market with improving profitability margins.
The outlook remains positive with analyst consensus favoring Buy ratings (61%) and a $34 price target representing 3% upside. Key opportunities include AI revenue expansion and market leadership, while risks involve insider selling activity and competitive pressures in the CCaaS space. The company's transition to profitability and strong subscription growth support continued investor interest.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →